Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 219 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naprosyn Clear all
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

NCT00382993
View directory record Official record
Conditions
Migraine Disorders
Interventions
Placebo, Combination Product (sumatriptan succinate/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 22, 2026, 3:34 AM EDT
Withdrawn Phase 2 Interventional

Novel Non-opioid Post-surgical Pain Treatment in Females

NCT05087914
View directory record Official record
Conditions
Acute Pain, Bunionectomy, Toe Fusion
Interventions
Carbidopa-Levodopa (100mg/25mg):, Naproxen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 22, 2026, 3:34 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Multiple-Dose Safety Study of Fixed Combination of Acetaminophen/Naproxen Sodium in Adolescents With Orthodontic Pain

NCT05845008
View directory record Official record
Conditions
Orthodontic Pain
Interventions
Acetaminophen/Naproxen Sodium Fixed Combination
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 16 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels

NCT00749385
View directory record Official record
Conditions
Arthritis
Interventions
PN 400, EC naproxen plus EC esomeprazole, EC naproxen, EC esomeprazole
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2008 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Not applicable Interventional

Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study

NCT00303017
View directory record Official record
Conditions
Osteoarthritis
Interventions
flavocoxid, Naproxen
Dietary Supplement · Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 3 Interventional

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240617
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 22, 2026, 3:34 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effectiveness of Synapse Transcutaneous Electronic Nerve Stimulation (TENS) During Dental Procedures Among Children

NCT03779659
View directory record Official record
Conditions
Dental Fear, Anesthesia, Local, Pediatric Dentistry
Interventions
Synapse TENS device, Topical anesthetic gel
Device · Drug
Lead sponsor
Boston University
Other
Eligibility
6 Years to 14 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 4 Interventional Results available

Ictal and Interictal Inflammatory Markers in Migraine

NCT01138150
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

NCT00665743
View directory record Official record
Conditions
Arthritis
Interventions
PN400, naproxen
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2008 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea

NCT05900336
View directory record Official record
Conditions
Dysmenorrhea, Menstrual Pain, Non-steroidal Anti-inflammatory Drug
Interventions
Sodium Naproxen, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents

NCT00488514
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Tablet of Treximet (sumatriptan/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

NCT00652925
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 18 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
31
States / cities
San Diego, California • Hartford, Connecticut • Delray Beach, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2008 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Naproxen for Pain Control With Intrauterine Device Insertion

NCT02388191
View directory record Official record
Conditions
Contraception
Interventions
Naproxen sodium, Placebo tablet
Drug · Other
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

NCT00007189
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Naproxen Sodium (Aleve), Celecoxib (Celebrex)
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
70 Years and older
Enrollment
2,625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
6
States / cities
Sun City, Arizona • Tampa, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 22, 2026, 3:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers

NCT00442208
View directory record Official record
Conditions
Healthy
Interventions
PN 200
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03161093
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
58
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

NCT01688934
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 1 Interventional

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

NCT00662896
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
57
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

NCT00383162
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Fresno, California • Newport Beach, California • Santa Monica, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 22, 2026, 3:34 AM EDT
Terminated No phase listed Observational

Treximet Migraine Brain Imaging Research Study

NCT01112553
View directory record Official record
Conditions
Acute Migraine
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 22, 2026, 3:34 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 22, 2026, 3:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Predicting Patients' Response to Spinal Manipulation

NCT00285649
View directory record Official record
Conditions
Low Back Pain
Interventions
HVLA-SM, LVVA-SM, Usual Medical Care
Other
Lead sponsor
Palmer College of Chiropractic
Other
Eligibility
21 Years to 55 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Davenport, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 22, 2026, 3:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

NCT01147458
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 22, 2026, 3:34 AM EDT